Targeted therapy tested for tough prostate cancer cases

NCT ID NCT05457257

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study tested whether a targeted drug called olaparib works better than standard hormone treatments for Chinese men with advanced prostate cancer that has spread and stopped responding to other hormone therapies. The men in the study all had specific genetic changes (BRCA1/2 mutations). Researchers compared how long it took for the cancer to get worse or for patients to pass away while taking the different treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beijing, 100050, China
Research Site

Bengbu, 233004, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610000, China
Research Site

Chongqing, 408099, China
Research Site

Fuzhou, 350005, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510180, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310014, China
Research Site

Hefei, 230601, China
Research Site

Jiaxing, 314001, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250021, China
Research Site

Jining, 272029, China
Research Site

Kunming, 650101, China
Research Site

Lanzhou, 730030, China
Research Site

Linyi, 276000, China
Research Site

Nanchang, 330006, China
Research Site

Nantong, 226361, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200002, China
Research Site

Shanghai, 200032, China
Research Site

Shenyang, 110004, China
Research Site

Suzhou, 215004, China
Research Site

Taiyuan, 030000, China
Research Site

Tianjin, 300060, China
Research Site

Wanzhou, 404000, China
Research Site

Wuhan, 430022, China
Research Site

Wuxi, 214002, China
Research Site

Wuxi, 214023, China
Research Site

Xi'an, 710077, China
Research Site

Zhengzhou, 450052, China

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER